This is a working overview of research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-08. Anything still debated is marked as such rather than presented as settled.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
The study showed that MMP-3 accomplishes this damage by degrading claudin-5, occludin, and ZO-1 (another tight junction protein), similar to how MMP-3 damages the BBB. The increase in blood-brain barrier and blood-spinal cord barrier permeability allows for more neutrophils to infiltrate the brain and spinal cord at the site of inflammation. Neutrophils carry MMP-9., which has also been shown to degrade occludin. This leads to further disruption of the BBB and BSCB
== Cause == Scurvy, including subclinical scurvy, is caused by a deficiency of dietary vitamin C since the human liver is unable to synthesize vitamin C. Provided the diet contains sufficient vitamin C, the lack of working L-gulonolactone oxidase (GULO) enzyme has no significance. In modern Western societies, scurvy is seldom present in average adults, although underfed people (drug users, the homeless, neglected children and geriatrics) are affected. Virtually all commercially available baby formulas contain added vitamin C, preventing infantile scurvy. Human breast milk contains sufficient vitamin C if the mother has an adequate intake. Commercial milk is pasteurized, a heating process that destroys the natural vitamin C content of the milk. Scurvy is one of the accompanying diseases of malnutrition (other such micronutrient deficiencies are beriberi and pellagra) and thus is still widespread in areas of the world dependent on external food aid. Although rare, there are also documented cases of scurvy due to poor dietary choices by people living in industrialized nations.
=== Cold fusion === 208Pb(48Ca,xn)256−xNo (x=1,2,3,4) This cold fusion reaction was first studied in 1979 at Flerov Laboratory of Nuclear Reactions (FLNR). Further work in 1988 at GSI measured EC and SF branchings in 254No. In 1989, the FLNR used the reaction to measure SF decay characteristics for the two isomers of 254No. The measurement of the 2n excitation function was reported in 2001 by Yuri Oganessian at the FLNR. Patin et al. at the LBNL reported in 2002 the synthesis of 255–251No in the 1-4n exit channels and measured further decay data for these isotopes. The reaction has recently been used at Jyväskylän Yliopisto Fysiikan Laitos (JYFL) using the RITU set-up to study K-isomerism in 254No. The scientists were able to measure two K-isomers with half-lives of 275 ms and 198 s, respectively. They were assigned to 8− and 16+ K-isomeric levels. The reaction was used in 2004–5 at the FLNR to study the spectroscopy of 255–253No. The team were able to confirm an isomeric level in 253No with a half-life of 43.5 s.
Sources: en.wikipedia.org
=== Hydration and dehydration reactions === With judicious heating, gypsum converts to the partially dehydrated mineral called bassanite or plaster of Paris. This material has the formula CaSO4·(nH2O), where 0.5 ≤ n ≤ 0.8. Temperatures between 100 and 150 °C (212–302 °F) are required to drive off the water within its structure. The details of the temperature and time depend on ambient humidity. Temperatures as high as 170 °C (338 °F) are used in industrial calcination, but at these temperatures γ-anhydrite begins to form. The heat energy delivered to the gypsum at this time (the heat of hydration) tends to go into driving off water (as water vapor) rather than increasing the temperature of the mineral, which rises slowly until the water is gone, then increases more rapidly. The equation for the partial dehydration is:
=== Venezuela === Despite Castillo having recognized the Venezuelan government as democratic during the electoral campaign, Castillo's Vice Foreign Minister has claimed that Peru has declared that there is no legitimate authority within Venezuela since 5 January 2021. The Vice Foreign Minister has claimed that Peru supports "intra-Venezuelan dialogue" and a negotiated solution to the crisis. While not a recognition of the Maduro government, this represents a shift away from Peru's previous stance of backing the National Assembly, which opposes Maduro. The next day, then Prime Minister Guido Bellido rejected the Vice Foreign Minister's claims that Peru did not recognize a legitimate authority in Venezuela. Bellido claimed that the Vice Foreign Minister's claim was against the Peruvian government's position, and that President Castillo had a meeting with Venezuelan President Maduro to solve the Venezuelan migrant crisis. Bellido also implied that he was willing to replace the Foreign Ministry if they didn't like the government's stance on Venezuela. However, later that day, the Interior Minister Juan Carrasco claimed that although he respected Bellido's views, he backed the Foreign Ministry's stance regarding Peru's position on Venezuela. Castillo's meeting with President Maduro wasn't recorded on his official agenda. As such, Foreign Minister Óscar Maúrtua was summoned before Congress to explain on the matter. Maúrtua said that Castillo did not plan to meet with Nicolas Maduro, and that the meeting was brief.
== Biosynthesis == Alamethicin biosynthesis is hypothesized to be catalyzed by alamethicin synthase, a Nonribosomal peptide synthase (NRPS) first isolated in 1975. Although there are several sequences of the alamethicin peptide accepted, evidence suggests these all follow the general NRPS mechanism with small variations at select amino acids. Beginning with the acylation of the N terminal of the first aminoisobutiric acid on the ALM synthase enzyme by Acetyl-CoA, this is followed by the sequential condensation of amino acids by each modular unit of the synthetase. Amino acids are initially adenylated by an “adenylylation” (A) domain before being attached by a thioester bond to an Acyl Carrier Protein-like Peptidyl carrier protein. The growing chain is attached to the amino acid bearing PCP by the "condensation" (C) domain, followed by another round of the same reactions by the next module.
=== Pain === Codeine is used to treat mild to moderate pain. It is commonly used to treat post-surgical dental pain. Weak evidence indicates that it is useful in cancer pain, but it may have increased adverse effects, especially constipation, compared to other opioids. The American Academy of Pediatrics does not recommend its use in children due to side effects. The Food and Drug Administration (FDA) lists age under 12 years old as a contraindication to use.
Sources: en.wikipedia.org
His work on isotopes also led to his formulation of the whole number rule which states that "the mass of the oxygen isotope being defined [as 16], all the other isotopes have masses that are very nearly whole numbers", a rule that was used extensively in the development of nuclear energy. The exact mass of many isotopes was measured leading to the result that hydrogen has a 1% higher mass than expected by the average mass of the other elements. Aston speculated about the subatomic energy and the use of it in 1936. Isotopes and Mass-spectra and Isotopes are his most well-known books.
=== Golgi tendon organs === The Golgi tendon organ (GTO) is a proprioceptive organ that lies at the muscle-tendon junction. GTOs relay information through group Ib afferents, and encode active muscle force. As they are connected at one end to motor units, individual GTOs only relay information on a few fibers. At the same time, GTOs exhibit self-adaptation, in which GTO response decreases after prior activation, and cross-adaptation, in which GTO activity is modulated by prior activation of another GTO. Similar to muscle spindles, GTO firing is characterized by a heightened response at the onset of activity (dynamic response) and gradual relaxation to a resting firing rate (static response).
Muscle weakness is a lack of muscle strength. Its causes are numerous and can be divided into conditions associated with either true or perceived muscle weakness. True muscle weakness is a primary symptom of a variety of skeletal muscle diseases, including muscular dystrophy and inflammatory myopathy. It occurs in neuromuscular junction disorders, such as myasthenia gravis. Muscle weakness can also be caused by low levels of potassium and other electrolytes within muscle cells. It may be temporary or long-lasting, ranging from seconds or minutes to months or years. The term myasthenia is from my- from Greek μυο meaning "muscle" + -asthenia ἀσθένεια meaning "weakness".
=== Member requirements === The CLP required all members to study Marxist theoretical writings at weekly study sessions. Many members attended "cadre schools” which lasted for eight weeks, studying the Marxist classics full-time, six days a week. One of the CLP's fundamental positions was independence for the so-called "Negro Nation". They defined the Negro Nation as all people living in the Southern United States, including both African Americans and whites. The argument was that all those living within the boundaries of a nation were members of that nation.
The flowering period starts in June and continues into mid-summer, although in northern countries it flowers rather later, sometimes as late as September, when it can fail to set seed. Its chromosome number is 2n = 20.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.